JSB Market Research: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022

JSB Market Research: PharmaPoint:
Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022
On 9th August 2014

During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and
Humira are set to expire in the US in 2018 and 2016, respectively.
Overall, major barriers to the growth of the UC market include:
Email ID- [e-mail]
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

• Remicade and Humira losing patent protection in the mid-forecast
• Austerity measures favoring generic prescribing
• Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US
• In 2012, GlobalData estimates that the global UC market reached $4.2 billion across the 10 healthcare markets covered in our forecast: the US, France,
Germany, Italy, Spain, the UK, Japan, Canada, China, and India. By the end of the forecast period, in 2022, sales across these markets will grow steadily to reach
$6.6 billion, representing a Compound Annual Growth Rate (CAGR) of 4.8% over the 10-year timeframe.

Highlights
Key Questions Answered
• How will the UC market (sales and patient numbers) evolve over the 10-year forecast period from 2012 to 2022?
• Which brands and specific drug classes did physicians select for their UC patients in 2012 and how do they foresee their prescribing behavior evolving over the next five years?
• How will the launch of late-stage pipeline therapies such as Entyvio and
Kappaproct shape the future treatment landscape?
• What are the remaining unmet

Bibliography: 2012-2022 64 Table 10: 10MM, Incident Cases of UC, By Age, Both Sexes, N (Row %), 2012 65 Table 11: 10MM, Incident Cases of UC, By Sex, Ages ?10 Years, N (Row %), 2012 67 Table 12: 10MM, Prevalent Cases of UC, Ages ?10 Years, Both Sexes, N, Select Years, 2012-2022 71 Table 13: 10MM, Prevalent Cases of UC, By Age, Both Sexes, N (Row %), 2012 73 Table 14: 10MM, Prevalent Cases of UC, By Sex, Ages ?10 Years, N (Row %), 2012 Table 17: Treatment Guidelines for UC Used in the 10MM 84 Table 18: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013 85 Table 29: Leading Treatments for UC, 2014 112 Table 30: Product Profile - Remicade 115 Table 31: Remicade SWOT Analysis, 2014 119 Table 32: Global Sales Forecasts ($m) for Remicade, 2012-2022 120 Table 36: Humira SWOT Analysis, 2014 125 Table 37: Global Sales Forecasts ($m) for Humira, 2012-2022 126 Table 38: Product Profile - Simponi 128 Table 39: Simponi SWOT Analysis, 2014 130 Table 40: Global Sales Forecasts ($m) for Simponi, 2012-2022 131 Table 41: Product Profile - Apriso 133 Table 42: Apriso SWOT Analysis, 2014 135 Table 43: Global Sales Forecasts ($m) for Apriso, 2012-2022 136 Table 44: Product Profile - Asacol HD 138 Table 45: Asacol HD SWOT Analysis, 2014 141 Table 46: Global Sales Forecasts ($m) for Asacol HD, 2012-2022 142 Table 47: Product Profile - Lialda 143 Table 48: Lialda SWOT Analysis, 2014 145 Table 49: Global Sales Forecasts ($m) for Lialda, 2012-2022 146 Table 50: Product Profile - Pentasa 147 Table 51: Pentasa SWOT Analysis, 2014 149 Table 52: Global Sales Forecasts ($m) for Pentasa, 2012-2022 150